券商中国·2025-11-04 09:32Core Viewpoint - Public QDII funds are gradually increasing their positions in the US stock market, driven by the new narrative surrounding AI in healthcare, which has led to significant performance improvements for many funds [1][2]. Group 1: QDII Fund Positioning - Star fund managers, including Zhang Kun, have significantly increased their US stock holdings, with some funds reducing their exposure to Hong Kong stocks to mitigate risks during recent market adjustments [2][3]. - The GF Global Select Fund reported a 75% allocation to US stocks by the end of Q3, while the Hong Kong stock allocation dropped to approximately 3.72% [3]. - The E Fund Global Growth Select Fund also saw its US stock allocation rise to 52%, with only about 10% in Hong Kong stocks [3]. Group 2: Performance of QDII Funds - The core reason for the increase in US stock holdings among QDII fund managers is the high elasticity exhibited by the AI healthcare sector in the US market [5]. - QDII funds focusing on US stocks have dominated performance rankings, with the E Fund Global Growth Select Fund achieving a 39% return over the past three months [5]. - Funds with minimal exposure to Hong Kong stocks, such as the CCB New Emerging Markets Mixed Fund, reported an 11% return in the last month, ranking first among QDII funds [5]. Group 3: Investment in AI Healthcare - The recent surge in US AI healthcare investments by major companies like Nvidia, Microsoft, and Google has significantly contributed to the performance of QDII funds [6][7]. - The CCB Global Pharmaceutical Fund's manager completely liquidated its Hong Kong stock holdings, increasing its US stock allocation to 71% by the end of September [4]. - Fund managers are optimistic about the potential of AI healthcare, viewing it as a key area for growth, especially as the US leads in this sector [8][9].